The association between the neutralizing activity and the amount of antibody in the convalescence stage of SARS-CoV-2 infection: A multicenter observational study

Not Applicable

• Conditions: COVID-19 (SARS-CoV-2 infection)

• Registration Number: JPRN-UMIN000041021
• Lead Sponsor: Yokohama City University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-07
• Study Completion: 2021-07-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who meet the following criteria are excluded. (1) Patients with mental illness or other conditions that might affect their ability to consent (2) Patients who are deemed by the researcher to be unsuitable to participate in the research.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation of neutralizing activity and NP antibody titers against SARS-CoV-2 at 26 (20 - 32) and 52 (46 - 58) weeks after the date of the first positive PCR or other test for COVID-19

Secondary Outcome Measures

Name	Time	Method
(1) Correlation between neutralizing activity and NP antibody titer by severity of illness (severe cases requiring tracheal intubation or ECMO) (2) Distribution of NP antibodies (quantitative and qualitative), SP antibodies (quantitative), and neutralizing activity at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test for COVID-19 by sex and age group (3) Correlation between neutralizing activity and SP antibody titers at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive test for COVID-19, including PCR (4) Association of baseline background factors, hospitalization status, treatment status, and severity of disease with neutralizing activity values at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test. (5) Association of baseline background factors, treatment status, and severity of disease with NP antibody titers at 26 (20 - 32) and 52 (46 - 58) weeks after the first positive PCR or other test for COVID-19.